Numerion Labs vs Valo Health (2026)
Where the AI sits is the difference between Numerion Labs and Valo Health: Numerion uses it to find and optimize molecules for a known protein, Valo to decide which protein matters in patients. Both develop small molecules and both have worked with large drug companies. Numerion, the company formerly known as Atomwise, builds on structure. COSMOS, its chemistry foundation model, predicts binding and function; APEX enumerates very large virtual libraries, and in research with NVIDIA it retrieved the top one million compounds from ten billion in under 30 seconds on a single GPU; and EXPO optimizes binders into candidates. Its predecessor model, AtomNet, was tested in the AIMS study across 318 prospective projects and found active compounds in 73% of the academic ones. Numerion now develops its own programs in immune and inflammatory disease. Valo starts with de identified patient histories, more than 17 million of them, finds subtypes and causal targets, checks them in human data and then designs small molecules in a loop with its laboratory. Its partners, including Novo Nordisk and Merck KGaA, lead clinical development. For a program where the target structure is known and the need is hits from enormous chemical libraries, Numerion's tools and AtomNet's published record are the reference. For a program where the target itself needs to come from human evidence, Valo fits.
- The target has a known structure and the program needs hits fast.
- Screening billions of virtual compounds is part of the plan.
- Published prospective hit rates for the predecessor model matter to the decision.
- Immune and inflammatory disease is the shared area of interest.
- Human genetics and patient records should decide the target.
- The program wants patient subtypes defined before chemistry starts.
- A long running partnership across several programs is the goal.
- Model updates after each laboratory round are expected of the discovery partner.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Numerion Labs and Valo Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Numerion Labs | Valo Health |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Headquarters | San Francisco, CA | Lexington, Massachusetts |
| Website | numerionlabs.ai | valohealth.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
Numerion Labs, formerly Atomwise, finds and optimizes small molecules with COSMOS, a chemistry foundation model, APEX for searching billions of virtual compounds and EXPO for optimization, and develops its own immune and inflammatory disease programs.
Source: AI Health Index, October 2026
Valo Health begins with the patient rather than the protein structure, finding targets through causal analysis of de identified records before its chemistry loop designs and refines small molecules.
Source: AI Health Index, October 2026
Questions buyers ask
What evidence backs Numerion Labs' and Valo Health's platforms?
Numerion's predecessor model, AtomNet, has the AIMS study in Scientific Reports, with hits in 215 of 296 academic projects, and its current tools have benchmark results such as the APEX search with NVIDIA. Valo's platform has no clinical result yet, and its partner Novo Nordisk reports targets identified through their work. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 13, 2026. No vendor pays for placement.
Which of Numerion Labs and Valo Health works from patient data?
Valo does, with de identified records that in some cases span 20 to 30 years. Numerion works from protein targets and chemical libraries and asks people not to send health information through its service. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 13, 2026. No vendor pays for placement.
Are Numerion Labs and Valo Health open to partners?
Valo describes a dual model of its own pipeline plus partnerships in which partners lead clinical development and Valo keeps royalties. Numerion signed collaborations as Atomwise with Sanofi, Hansoh Pharma and Eli Lilly and now presents itself mainly through its own programs. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 13, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Numerion Labs is based in San Francisco and led by chief executive Steve Worland. Valo Health has its base in Lexington, Massachusetts. Numerion publishes no current partnership terms, and Valo's Novo Nordisk deal is the one it has made public.